

OnabotulinumtoxinA for Treatment of Chronic Migraine Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial

Headache

50, 921-936

DOI: [10.1111/j.1526-4610.2010.01678.x](https://doi.org/10.1111/j.1526-4610.2010.01678.x)

Citation Report

#	ARTICLE	IF	CITATIONS
2	FDA Approves Botulinum A Toxin for Severe Chronic Migraine. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2010, 10, 1.	0.0	0
3	Guide to properties and efficacy of drugs used in migraine. <i>The Prescriber</i> , 2010, 21, 22-41.	0.1	0
4	Chronic migraine: comorbidities, risk factors, and rehabilitation. <i>Internal and Emergency Medicine</i> , 2010, 5, 13-19.	1.0	82
5	Targeted Secretion Inhibitors—Innovative Protein Therapeutics. <i>Toxins</i> , 2010, 2, 2795-2815.	1.5	38
6	Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program. <i>Headache</i> , 2010, 50, 1406-1418.	1.8	191
7	Licence for Botox in so-called chronic migraine. <i>Lancet, The</i> , 2010, 376, 1825-1826.	6.3	13
8	Headaches: Psychiatric Aspects. <i>Neurologic Clinics</i> , 2011, 29, 65-80.	0.8	12
9	Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. <i>Parkinsonism and Related Disorders</i> , 2011, 17, S28-S33.	1.1	109
10	New and emerging indications of botulinum toxin therapy. <i>Parkinsonism and Related Disorders</i> , 2011, 17, S25-S27.	1.1	6
11	Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. <i>Neuroscience</i> , 2011, 186, 201-207.	1.1	176
12	Botulinum toxin—Beyond wrinkles. <i>Techniques in Regional Anesthesia and Pain Management</i> , 2011, 15, 69-73.	0.2	1
14	Aesthetic nursing: the case for safe prescribing. <i>NursePrescribing</i> , 2011, 9, 144-149.	0.1	4
16	What Predicts Remission from Chronic Migraine?. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2011, 11, 8-9.	0.0	0
19	Treatment of medication overuse headache - guideline of the EFNS headache panel. <i>European Journal of Neurology</i> , 2011, 18, 1115-1121.	1.7	168
20	Prevalence and Burden of Chronic Migraine in Adolescents: Results of the Chronic Daily Headache in Adolescents Study (C&AS). <i>Headache</i> , 2011, 51, 693-706.	1.8	130
21	Frovatriptan for Prophylactic Treatment of Cluster Headache. <i>Headache</i> , 2011, 51, 1008-1009.	1.8	6
22	OnabotulinumtoxinA for Treatment of Chronic Migraine. <i>Headache</i> , 2011, 51, 1002-1003.	1.8	3
24	Botulinum Toxin for the Treatment of Chronic Migraine: The Placebo Effect. <i>Headache</i> , 2011, 51, 980-984.	1.8	19

#	ARTICLE	IF	CITATIONS
25	OnabotulinumtoxinA for Treatment of Chronic Migraine: A Response. <i>Headache</i> , 2011, 51, 1005-1008.	1.8	2
26	Understanding Migraine: A Tale of Hope and Frustration. <i>Headache</i> , 2011, 51, 1188-1190.	1.8	6
27	Implications of Current Clinical Trials Focused on Medication Overuse and Therapeutic Prophylaxis. <i>Headache</i> , 2011, 51, 93-100.	1.8	0
28	OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program. <i>Headache</i> , 2011, 51, 1358-1373.	1.8	243
29	Treatment of Refractory Pain with Botulinum Toxins—An Evidence-Based Review. <i>Pain Medicine</i> , 2011, 12, 1594-1606.	0.9	81
30	A randomized controlled trial on medication-overuse headache: outcome after 1 and 4 years. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 38-43.	1.0	26
31	Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study. <i>Pain</i> , 2011, 152, 1988-1996.	2.0	127
32	Chemical composition and therapeutic effects of <i>Lippia alba</i> (Mill.) N. E. Brown leaves hydro-alcoholic extract in patients with migraine. <i>Phytomedicine</i> , 2011, 18, 1197-1201.	2.3	23
33	Botox for the prophylaxis of headaches in chronic migraine. <i>The Prescriber</i> , 2011, 22, 13-18.	0.1	0
36	Migraine prophylaxis: what is new and what we need?. <i>Neurological Sciences</i> , 2011, 32, 111-115.	0.9	21
37	Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks. <i>Journal of Headache and Pain</i> , 2011, 12, 235-238.	2.5	33
38	Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine. <i>Journal of Headache and Pain</i> , 2011, 12, 135-136.	2.5	7
39	Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine. <i>Journal of Headache and Pain</i> , 2011, 12, 137-138.	2.5	4
40	Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. <i>Journal of Headache and Pain</i> , 2011, 12, 427-433.	2.5	100
41	CONSORT recommendations in abstracts of randomised, controlled trials on migraine and headache. <i>Journal of Headache and Pain</i> , 2011, 12, 505-510.	2.5	5
42	Chronic migraine plus medication overuse headache: two entities or not?. <i>Journal of Headache and Pain</i> , 2011, 12, 593-601.	2.5	87
43	Chronic Migraine: Epidemiology and Disease Burden. <i>Current Pain and Headache Reports</i> , 2011, 15, 70-78.	1.3	176
44	Treatment of Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2011, 15, 64-69.	1.3	43

#	ARTICLE	IF	CITATIONS
45	Treatment of Chronic Migraine Headache with OnabotulinumtoxinA. Current Pain and Headache Reports, 2011, 15, 336-338.	1.3	8
46	Botulinum Toxin: Clinical Techniques, Applications, and Complications. Facial Plastic Surgery, 2011, 27, 529-539.	0.5	21
47	Progress in headache mechanisms and management. Nature Reviews Neurology, 2011, 7, 67-68.	4.9	5
48	Chronic Daily Headache. Neurology, 2011, 76, S37-43.	1.5	29
49	Pressure-painful scalp arteries in children and adolescents suffering from migraine. Cephalalgia, 2011, 31, 1576-1579.	1.8	3
50	Onabotulinum toxin A treatment of cervicogenic headache: A randomised, double-blind, placebo-controlled crossover study. Cephalalgia, 2011, 31, 797-807.	1.8	29
51	OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology, 2011, 77, 1465-1472.	1.5	130
52	A Dileucine in the Protease of Botulinum Toxin A Underlies Its Long-lived Neuroparalysis. Journal of Biological Chemistry, 2011, 286, 6375-6385.	1.6	78
53	Acupuncture versus topiramate in chronic migraine prophylaxis: A randomized clinical trial. Cephalalgia, 2011, 31, 1510-1521.	1.8	102
54	Needling the pain and comforting the brain: Acupuncture in the treatment of chronic migraine. Cephalalgia, 2011, 31, 1507-1509.	1.8	9
55	Botox for chronic migraine. Drug and Therapeutics Bulletin, 2011, 49, 22-24.	0.3	3
56	Headache. Seminars in Neurology, 2011, 31, 005-017.	0.5	18
57	Review of posttraumatic stress disorder and chronic pain: The path to integrated care. Journal of Rehabilitation Research and Development, 2012, 49, 753.	1.6	55
58	Combination therapy for chronic migraine. Neurology, 2012, 78, 940-941.	1.5	8
59	Chronic daily headaches. Annals of Indian Academy of Neurology, 2012, 15, 40.	0.2	11
60	Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology, 2012, 78, 976-984.	1.5	76
61	Ten-Year Follow-Up in a Case Series of Integrative Botulinum Toxin Intervention in Adolescents with Chronic Daily Headache and Associated Muscle Pain. Neuropediatrics, 2012, 43, 339-345.	0.3	15
62	Posttraumatic headache. Current Opinion in Neurology, 2012, 25, 284-289.	1.8	22

#	ARTICLE	IF	CITATIONS
63	Special Considerations and Recommendations for Interventions for Pediatric Chronic Pain. <i>International Anesthesiology Clinics</i> , 2012, 50, 120-129.	0.3	5
64	Detoxification for medication overuse headache is not necessary. <i>Cephalalgia</i> , 2012, 32, 423-427.	1.8	49
65	The role of the neurovascular scalp structures in migraine. <i>Cephalalgia</i> , 2012, 32, 778-784.	1.8	11
66	Occipital nerve stimulation for chronic migraine: Already advised?. <i>Cephalalgia</i> , 2012, 32, 1163-1164.	1.8	8
70	Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 35.	1.0	23
72	Botulinum toxin in the treatment of post-traumatic headache – case study. <i>Neurologia i Neurochirurgia Polska</i> , 2012, 46, 591-594.	0.6	12
73	OnabotulinumtoxinA (BOTOX®): A Guide to Its Use in Preventing Headaches in Adults with Chronic Migraine. <i>CNS Drugs</i> , 2012, 26, 717-723.	2.7	2
74	Commentary: Development and validation of the Asian Migraine Criteria (AMC). <i>Journal of Clinical Neuroscience</i> , 2012, 19, 229-230.	0.8	2
75	Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. <i>Current Opinion in Pharmacology</i> , 2012, 12, 100-108.	1.7	69
76	Preventive Treatment of Migraine. <i>Headache</i> , 2012, 52, 65-69.	1.8	10
77	Let's Give Botox a Brake. <i>Headache</i> , 2012, 52, 1602-1603.	1.8	1
78	OnabotulinumtoxinA (BOTOX®). <i>Drugs</i> , 2012, 72, 825-845.	4.9	34
79	Chronic migraine – classification, characteristics and treatment. <i>Nature Reviews Neurology</i> , 2012, 8, 162-171.	4.9	130
80	Emerging treatment for chronic migraine and refractory chronic migraine. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 393-406.	1.0	63
81	OnabotulinumtoxinA in the treatment of migraine headache. <i>Techniques in Regional Anesthesia and Pain Management</i> , 2012, 16, 41-46.	0.2	1
82	Chronic migraine: a therapeutic challenge for clinicians. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 445-447.	1.0	4
85	55 Therapie der Migräne. , 2012, , .		13
86	Headaches and Other Head Pain. , 2012, , 2246-2252.		1

#	ARTICLE	IF	CITATIONS
87	Future trends in drugs for migraine prophylaxis. <i>Neurological Sciences</i> , 2012, 33, 137-140.	0.9	2
89	Nocebo in Headaches: Implications for Clinical Practice and Trial Design. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 132-137.	2.0	42
90	OnabotulinumtoxinA in Pediatric Chronic Daily Headache. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 114-117.	2.0	51
92	Italian guidelines for primary headaches: 2012 revised version. <i>Journal of Headache and Pain</i> , 2012, 13, 31-70.	2.5	129
93	OnabotulinumtoxinA for Chronic Migraine. <i>Headache</i> , 2012, 52, 142-148.	1.8	7
94	Validating Migraine-specific Quality of Life Questionnaire v2.1 in Episodic and Chronic Migraine. <i>Headache</i> , 2012, 52, 409-421.	1.8	98
95	Concurrent OnabotulinumtoxinA Treatment of Cervical Dystonia and Concomitant Migraine. <i>Headache</i> , 2012, 52, 1219-1225.	1.8	21
96	Utilization of Topiramate During Pregnancy and Risk of Birth Defects. <i>Headache</i> , 2012, 52, 1070-1084.	1.8	28
97	Let's Give Botox a Break. <i>Headache</i> , 2012, 52, 1204-1205.	1.8	3
98	Adherence with Migraine Prophylaxis in Clinical Practice. <i>Pain Practice</i> , 2012, 12, 541-549.	0.9	91
99	Facing depression with botulinum toxin: A randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2012, 46, 574-581.	1.5	175
100	Defining the Differences Between Episodic Migraine and Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2012, 16, 86-92.	1.3	211
101	Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. <i>Journal of Headache and Pain</i> , 2012, 13, 53-59.	2.5	38
102	Molecular components required for resting and stimulated endocytosis of botulinum neurotoxins by glutamatergic and peptidergic neurons. <i>FASEB Journal</i> , 2013, 27, 3167-3180.	0.2	21
104	Enhancing Medical Education by Improving Statistical Methodology in Journal Articles. <i>Teaching and Learning in Medicine</i> , 2013, 25, 159-164.	1.3	3
105	Therapeutic prospects for migraine: Can paradise be regained?. <i>Annals of Neurology</i> , 2013, 74, 423-434.	2.8	22
106	OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. <i>Journal of the Neurological Sciences</i> , 2013, 331, 48-56.	0.3	168
107	The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. <i>Journal of Medical Economics</i> , 2013, 16, 877-887.	1.0	45

#	ARTICLE	IF	CITATIONS
108	OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT. <i>Journal of Headache and Pain</i> , 2013, 14, .	2.5	3
109	A six year retrospective review of occipital nerve stimulation practice - controversies and challenges of an emerging technique for treating refractory headache syndromes. <i>Journal of Headache and Pain</i> , 2013, 14, 67.	2.5	77
110	Disability and quality of life in headache: where we are now and where we are heading. <i>Neurological Sciences</i> , 2013, 34, 1-5.	0.9	24
111	Opioids can be useful in the treatment of headache. <i>Neurological Sciences</i> , 2013, 34, 119-124.	0.9	9
113	<scp>OnabotulinumtoxinA</scp> for the Treatment of Headache. <i>Headache</i> , 2013, 53, 54-61.	1.8	40
114	Patients profiling for Botox® (onabotulinum toxin A) treatment for migraine: a look at white matter lesions in the MRI as a potential marker. <i>SpringerPlus</i> , 2013, 2, 377.	1.2	10
116	Hemicrania Continua Responsive to Botulinum Toxin Type <scp>A</scp>: A Case Report. <i>Headache</i> , 2013, 53, 831-833.	1.8	15
117	Valutazione economica della tossina botulinica per la profilassi dell'emicrania cronica. <i>Pharmacoeconomics Italian Research Articles</i> , 2013, 15, 19-33.	0.2	2
118	Comparison of analgesic effects of single versus repeated injection of botulinum toxin in orofacial formalin test in rats. <i>Journal of Neural Transmission</i> , 2013, 120, 141-144.	1.4	9
119	Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations. <i>Journal of Neural Transmission</i> , 2013, 120, 291-298.	1.4	15
120	Medication Overuse Headaches. <i>Medical Clinics of North America</i> , 2013, 97, 337-352.	1.1	31
121	Involvement of μ -opioid receptors in antinociceptive action of botulinum toxin type A. <i>Neuropharmacology</i> , 2013, 70, 331-337.	2.0	52
122	The rat Digit Abduction Score (DAS) assay: A physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis. <i>Toxicon</i> , 2013, 71, 18-24.	0.8	40
123	A Rational Approach to the Management of Chronic Migraine. <i>Headache</i> , 2013, 53, 168-176.	1.8	32
124	Two Mechanisms Involved in Trigeminal CGRP Release: Implications for Migraine Treatment. <i>Headache</i> , 2013, 53, 67-80.	1.8	61
125	Lippia alba (Mill.) N. E. Brown hydroethanolic extract of the leaves is effective in the treatment of migraine in women. <i>Phytomedicine</i> , 2013, 20, 947-950.	2.3	20
126	Interdisciplinary management of headache disorders. <i>Techniques in Regional Anesthesia and Pain Management</i> , 2013, 17, 174-187.	0.2	4
128	Migren Tedavisinde Botulinum Toksini. <i>Noropsikiyatri Arsivi</i> , 2013, 50, 36-40.	0.7	3

#	ARTICLE	IF	CITATIONS
129	Chronic migraine and chronic daily headache in the Asia-Pacific region: A systematic review. <i>Cephalalgia</i> , 2013, 33, 266-283.	1.8	49
130	Predicting Prognostic Factors in a Randomized Controlled Trial of Acupuncture Versus Topiramate Treatment in Patients With Chronic Migraine. <i>Clinical Journal of Pain</i> , 2013, 29, 982-987.	0.8	15
131	Botulinum Toxin in the Management of Painful Conditions. , 2013, , 563-573.		0
132	Cognitive Behavioral Therapy Plus Amitriptyline for Chronic Migraine in Children and Adolescents. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2622.	3.8	229
133	An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. <i>JRSM Short Reports</i> , 2013, 4, 1-9.	0.6	72
134	Migrende Profilaktik Tedavi. <i>Noropsikiyatri Arsivi</i> , 2013, 50, 30-35.	0.7	5
135	Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 65-72.	1.0	19
136	Rounding Behavior in the Reporting of Headache Frequency Complicates Headache Chronification Research. <i>Headache</i> , 2013, 53, 908-919.	1.8	25
138	Peripheral occipital nerve stimulation to treat chronic refractory migraine. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 85-89.	0.2	4
140	Latin American consensus on guidelines for chronic migraine treatment. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 478-486.	0.3	25
141	Chronic daily headache. , 0, , 95-105.		0
142	Blockade of Glutamate Release by Botulinum Neurotoxin Type A in Humans: A Dermal Microdialysis Study. <i>Pain Research and Management</i> , 2014, 19, 126-132.	0.7	22
143	Tackling chronic migraine: current perspectives. <i>Journal of Pain Research</i> , 2014, 7, 185.	0.8	29
144	Chronic Daily Headache in Korea: Prevalence, Clinical Characteristics, Medical Consultation and		

#	ARTICLE	IF	CITATIONS
150	Therapeutic use of botulinum toxin in migraine: mechanisms of action. <i>British Journal of Pharmacology</i> , 2014, 171, 4177-4192.	2.7	78
151	OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the <sc>PREEMPT</sc> clinical program. <i>Acta Neurologica Scandinavica</i> , 2014, 129, 61-70.	1.0	140
152	Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. <i>Journal of Headache and Pain</i> , 2014, 15, 54.	2.5	105
153	The role of headache chronicity among predictors contributing to quality of life in patients with migraine: a hospital-based study. <i>Journal of Headache and Pain</i> , 2014, 15, 68.	2.5	51
154	Botulinum toxin type A products are not interchangeable: a review of the evidence. <i>Biologics: Targets and Therapy</i> , 2014, 8, 227.	3.0	70
155	Development of onabotulinumtoxinA for chronic migraine. <i>Annals of the New York Academy of Sciences</i> , 2014, 1329, 67-80.	1.8	44
156	Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial. <i>Neurology International</i> , 2014, 6, 5133.	1.3	19
157	Time Course Analysis of the Effects of Botulinum Neurotoxin Type A on Pain and Vasomotor Responses Evoked by Glutamate Injection into Human Temporalis Muscles. <i>Toxins</i> , 2014, 6, 592-607.	1.5	19
158	Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine. <i>Headache</i> , 2014, 54, 1565-1573.	1.8	38
159	Consensus treatment of medication overuse headache in Latin America and Europe. <i>Cephalalgia</i> , 2014, 34, 643-644.	1.8	2
160	Refractory chronic migraine: a Consensus Statement on clinical definition from the European Headache Federation. <i>Journal of Headache and Pain</i> , 2014, 15, 47.	2.5	86
161	Analysis of the duration of migraine prophylaxis. <i>Journal of the Neurological Sciences</i> , 2014, 337, 38-41.	0.3	8
162	Emerging Targets in Migraine. <i>CNS Drugs</i> , 2014, 28, 11-17.	2.7	43
163	Economic Burden and Costs of Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2014, 18, 385.	1.3	97
165	Medication-overuse headache: epidemiology, diagnosis and treatment. <i>Therapeutic Advances in Drug Safety</i> , 2014, 5, 87-99.	1.0	116
168	Improving the Classification of Migraine Subtypes: An Empirical Approach Based on Factor Mixture Models in the <sc>American</sc> <sc>Migraine</sc> <sc>Prevalence and</sc> <sc>Prevention</sc> (<sc>AMPP</sc>) Study. <i>Headache</i> , 2014, 54, 830-849.	1.8	32
169	Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. <i>European Journal of Neurology</i> , 2014, 21, 851-859.	1.7	47
171	Safety of topiramate for treating migraines. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1241-1247.	1.0	17

#	ARTICLE	IF	CITATIONS
172	Glutamate Receptor Antagonists in the Management of Migraine. <i>Drugs</i> , 2014, 74, 1165-1176.	4.9	40
173	Evaluation of headache relief with cosmetic onabotulinumtoxinA injections. <i>Journal of Cosmetic Dermatology</i> , 2014, 13, 224-231.	0.8	0
174	Technique of injection of onabotulinumtoxin A for chronic migraine: the PREEMPT injection paradigm. <i>Neurological Sciences</i> , 2014, 35, 41-43.	0.9	8
175	The cost effectiveness of Botox in Italian patients with chronic migraine. <i>Neurological Sciences</i> , 2014, 35, 45-47.	0.9	22
176	The setting of a botulinum toxin treatment service. <i>Neurological Sciences</i> , 2014, 35, 49-50.	0.9	5
177	Peripheral neurostimulation in primary headaches. <i>Neurological Sciences</i> , 2014, 35, 77-81.	0.9	19
178	Onabotulinumtoxin A for prophylaxis in chronic migraine: preliminary data from headache regional centre of aosta valley. <i>Neurological Sciences</i> , 2014, 35, 175-176.	0.9	5
179	Operational Diagnostic Criteria for Chronic Migraine: Expert Opinion. <i>Headache</i> , 2014, 54, 1258-1266.	1.8	32
180	Chronic migraine. <i>BMJ, The</i> , 2014, 348, g1416-g1416.	3.0	187
181	Botulinum toxin B in the sensory afferent: Transmitter release, spinal activation, and pain behavior. <i>Pain</i> , 2014, 155, 674-684.	2.0	62
182	Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: A retrospective study. <i>Journal of the Chinese Medical Association</i> , 2014, 77, 10-15.	0.6	24
183	Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons. <i>Pain</i> , 2014, 155, 1516-1526.	2.0	58
184	Botulinum toxin for the treatment of chronic pain. Review of the evidence. <i>Colombian Journal of Anesthesiology</i> , 2014, 42, 205-213.	0.5	5
185	Toxina botulínica para tratamiento del dolor crónico. Revisión de la evidencia. <i>Colombian Journal of Anesthesiology</i> , 2014, 42, 205-213.	0.5	13
186	Botulinum toxin A, brain and pain. <i>Progress in Neurobiology</i> , 2014, 119-120, 39-59.	2.8	137
188	Orofacial pain management: current perspectives. <i>Journal of Pain Research</i> , 2014, 7, 99.	0.8	160
189	The use of botulinum neurotoxin in the management of headache disorders. , 0, , 222-232.		0
190	Fibromuscular Dysplasia: An Update for the Headache Clinician. <i>Headache</i> , 2015, 55, 748-755.	1.8	16

#	ARTICLE	IF	CITATIONS
191	Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine. <i>Headache</i> , 2015, 55, 1218-1224.	1.8	22
192	Peripheral nerve blocks, steroid injections and their niche in headache medicine. <i>Cephalalgia</i> , 2015, 35, 850-852.	1.8	5
193	Modulation of inflammatory mediators in the trigeminal ganglion by botulinum neurotoxin type A: an organ culture study. <i>Journal of Headache and Pain</i> , 2015, 16, 555.	2.5	27
194	A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. <i>Journal of Headache and Pain</i> , 2015, 17, 1.	2.5	120
195	Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse. <i>SpringerPlus</i> , 2015, 4, 589.	1.2	30
196	OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. <i>SpringerPlus</i> , 2015, 4, 826.	1.2	62
197	Botulinum Toxin in Pediatric Neurology. <i>Global Pediatric Health</i> , 2015, 2, 2333794X1559014.	0.3	1
198	Neurotoxins. <i>Plastic and Reconstructive Surgery</i> , 2015, 136, 104S-110S.	0.7	15
199	The Effects of Intraplantar and Intrathecal Botulinum Toxin Type B on Tactile Allodynia in Mono and Polyneuropathy in the Mouse. <i>Anesthesia and Analgesia</i> , 2015, 121, 229-238.	1.1	9
200	An Association between Carpal Tunnel Syndrome and Migraine Headachesâ€”National Health Interview Survey, 2010. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2015, 3, e333.	0.3	12
201	Resolution of chronic migraine headaches with intrathecal ziconotide: a case report. <i>Journal of Pain Research</i> , 2015, 8, 603.	0.8	5
202	OnabotulinumtoxinA for chronic migraine: a critical appraisal. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1003.	0.9	20
203	Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins. <i>Toxins</i> , 2015, 7, 2615-2628.	1.5	23
204	Topographic Relationship between the Supratrochlear Nerve and Corrugator Supercilii Muscleâ€”Can This Anatomical Knowledge Improve the Response to Botulinum Toxin Injections in Chronic Migraine?. <i>Toxins</i> , 2015, 7, 2629-2638.	1.5	22
205	Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety. <i>Toxins</i> , 2015, 7, 2659-2673.	1.5	20
206	Temporomandibular Myofacial Pain Treated with Botulinum Toxin Injection. <i>Toxins</i> , 2015, 7, 2791-2800.	1.5	49
207	Botulinum Toxin Type A as a Therapeutic Agent against Headache and Related Disorders. <i>Toxins</i> , 2015, 7, 3818-3844.	1.5	55
208	Current Status and Future Directions of Botulinum Neurotoxins for Targeting Pain Processing. <i>Toxins</i> , 2015, 7, 4519-4563.	1.5	61

#	ARTICLE	IF	CITATIONS
209	Botulinum Toxin for Neuropathic Pain: A Review of the Literature. <i>Toxins</i> , 2015, 7, 3127-3154.	1.5	110
210	Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. <i>International Journal of General Medicine</i> , 2015, 8, 79.	0.8	51
211	Evidence-Based Treatments for Adults with Migraine. <i>Pain Research and Treatment</i> , 2015, 2015, 1-13.	1.7	17
212	Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine. <i>Neurological Sciences</i> , 2015, 36, 29-32.	0.9	23
213	Chronic Migraine. , 2015, , 99-122.		1
214	Best Practices for Patients With Chronic Migraine. <i>Mayo Clinic Proceedings</i> , 2015, 90, 408-414.	1.4	33
215	New players in the preventive treatment of migraine. <i>BMC Medicine</i> , 2015, 13, 279.	2.3	38
216	Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 996-1001.	0.9	105
217	Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example. <i>Journal of Pain</i> , 2015, 16, 164-175.	0.7	49
218	Drug safety and tolerability in prophylactic migraine treatment. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 667-681.	1.0	43
219	Cefalea (II). <i>Migraña. Medicina</i> , 2015, 11, 4155-4166.	0.0	0
220	TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 393-397.	0.9	46
221	TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. Some like it hot! Chronic migraine increases TRPV1 receptors in the scalp. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 361-361.	0.9	8
222	Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents. <i>Neurobiology of Disease</i> , 2015, 79, 111-122.	2.1	32
223	Migraine and neuropeptides. <i>Neuropeptides</i> , 2015, 52, 19-30.	0.9	99
224	Costo beneficio del tratamiento de la migraña crónica con Onabotulinumtoxin A en Argentina. <i>Neurología Argentina</i> , 2015, 7, 84-88.	0.1	0
225	Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience. <i>Neurological Sciences</i> , 2015, 36, 33-35.	0.9	32
226	Botulinum neurotoxin: Progress in negating its neurotoxicity; and in extending its therapeutic utility via molecular engineering. <i>MiniReview. Peptides</i> , 2015, 72, 80-87.	1.2	5

#	ARTICLE	IF	CITATIONS
227	Update on Medication-Overuse Headache and Its Treatment. Current Treatment Options in Neurology, 2015, 17, 368.	0.7	12
228	Lack of association between oxidative stress-related gene polymorphisms and chronic migraine in an Italian population. Expert Review of Neurotherapeutics, 2015, 15, 215-225.	1.4	11
229	The Efficacy of Botulinum Toxin A in Post-Mastectomy Breast Reconstruction: A Pilot Study. Aesthetic Surgery Journal, 2015, 35, 402-409.	0.9	31
230	OnabotulinumtoxinA for Hemicrania Continua: open label experience in 9 patients. Journal of Headache and Pain, 2015, 16, 19.	2.5	19
231	OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. SpringerPlus, 2015, 4, 176.	1.2	38
232	Targeting pericranial nerve branches to treat migraine: Current approaches and perspectives. Cephalalgia, 2015, 35, 1308-1322.	1.8	26
233	Advanced Headache Therapy. , 2015, , .		1
234	Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurology, 2015, 15, 100.	0.8	25
235	A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine. Current Pain and Headache Reports, 2015, 19, 49.	1.3	17
236	Botulinum toxin and the treatment of headache: A clinical review. Toxicon, 2015, 107, 114-119.	0.8	12
237	No Microstructural White Matter Alterations in Chronic and Episodic Migraineurs: A Caseâ€“Control Diffusion Tensor Magnetic Resonance Imaging Study. Headache, 2015, 55, 241-251.	1.8	44
238	Drug therapy in headache. Clinical Medicine, 2015, 15, 273-279.	0.8	9
239	Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options. Clinical Medicine, 2015, 15, 344-350.	0.8	58
240	What Constitutes an â€œAdequateâ€•Trial in Migraine Prevention?. Current Pain and Headache Reports, 2015, 19, 52.	1.3	1
241	Providing Care for Patients with Chronic Migraine: Diagnosis, Treatment, and Management. Pain Practice, 2015, 15, 688-692.	0.9	9
243	Diagnosis, pathophysiology and management of chronic migraine: a proposal of the Belgian Headache Society. Acta Neurologica Belgica, 2015, 115, 1-17.	0.5	15
244	Effects of OnabotulinumtoxinA on Habituation of Laser Evoked Responses in Chronic Migraine. Toxins, 2016, 8, 163.	1.5	22
245	Brain Changes in Responders vs. Non-Responders in Chronic Migraine: Markers of Disease Reversal. Frontiers in Human Neuroscience, 2016, 10, 497.	1.0	47

#	ARTICLE	IF	CITATIONS
246	Nocebo in headache. <i>Current Opinion in Neurology</i> , 2016, 29, 331-336.	1.8	23
247	Chronic migraine: risk factors, mechanisms and treatment. <i>Nature Reviews Neurology</i> , 2016, 12, 455-464.	4.9	391
248	Randomized Controlled Pilot Trial of Behavioral Insomnia Treatment for Chronic Migraine With Comorbid Insomnia. <i>Headache</i> , 2016, 56, 276-291.	1.8	80
249	Botulinum Toxin as Monotherapy in Symptomatic Trigeminal Neuralgia. <i>Headache</i> , 2016, 56, 1035-1039.	1.8	16
250	Onabotulinumtoxin-A treatment in Greek patients with chronic migraine. <i>Journal of Headache and Pain</i> , 2016, 17, 84.	2.5	27
251	Anatomical Regional Targeted (ART) BOTOX Injection Technique: A Novel Paradigm for Migraines and Chronic Headaches. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2016, 4, e1194.	0.3	18
252	Orofacial Pain. <i>Dental Clinics of North America</i> , 2016, 60, 381-405.	0.8	10
254	Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. <i>Journal of Headache and Pain</i> , 2016, 17, 48.	2.5	49
255	The use of onabotulinum toxin A (Botox®) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study. <i>Neurological Sciences</i> , 2016, 37, 1127-1131.	0.9	43
256	Anatomic and Compression Topography of the Lesser Occipital Nerve. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2016, 4, e639.	0.3	42
257	Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients: Table 1. <i>Brain</i> , 2016, 139, 2571-2577.	3.7	40
258	Long-Term Use and Safety of Migraine Preventive Medications. <i>Headache</i> , 2016, 56, 1335-1343.	1.8	9
259	Injection Therapy for Headache and Facial Pain. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2016, 28, 423-434.	0.4	12
260	Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. <i>Annals of Neurology</i> , 2016, 79, 569-578.	2.8	79
262	Cost impact of a non-invasive, portable device for patient self-administration of chronic migraine in a UK National Health Service setting. <i>SpringerPlus</i> , 2016, 5, 1249.	1.2	9
263	Medication-overuse headache: risk factors, pathophysiology and management. <i>Nature Reviews Neurology</i> , 2016, 12, 575-583.	4.9	197
264	Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine. <i>Neurological Sciences</i> , 2016, 37, 1779-1784.	0.9	25
265	Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A?. <i>Neurological Sciences</i> , 2016, 37, 1701-1706.	0.9	18

#	ARTICLE	IF	CITATIONS
266	Botulinum toxin. JAAPA: Official Journal of the American Academy of Physician Assistants, 2016, 29, 1-4.	0.1	2
268	TEV-48125 for the preventive treatment of chronic migraine. Neurology, 2016, 87, 41-48.	1.5	84
269	Chronic migraine treatment: from OnabotulinumtoxinA onwards. Expert Review of Neurotherapeutics, 2016, 16, 1217-1227.	1.4	22
270	OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program. Cephalalgia, 2016, 36, 899-908.	1.8	66
271	Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: A clinic-based prospective study. Journal of the Neurological Sciences, 2016, 363, 51-54.	0.3	30
272	Chronic Migraine in Children and Adolescents. Current Pain and Headache Reports, 2016, 20, 14.	1.3	17
273	The Use of Botulinum Toxin in the Management of Headache Disorders. Seminars in Neurology, 2016, 36, 092-098.	0.5	11
274	Update on the Pharmacological Treatment of Chronic Migraine. Current Pain and Headache Reports, 2016, 20, 6.	1.3	32
275	Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database. Cephalalgia, 2016, 36, 862-874.	1.8	30
276	Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update. Current Pain and Headache Reports, 2016, 20, 1.	1.3	47
277	Brief intervention by general practitioners for medication-overuse headache, follow-up after 6 months: a pragmatic cluster-randomised controlled trial. Journal of Neurology, 2016, 263, 344-353.	1.8	35
278	Outcome of Chronic Daily Headache or Chronic Migraine. Current Pain and Headache Reports, 2016, 20, 2.	1.3	8
279	Detoxification in medication-overuse headache, a retrospective controlled follow-up study: Does care by a headache nurse lead to cure?. Cephalalgia, 2016, 36, 122-130.	1.8	36
282	Treatment of medication-overuse headache: A systematic review. Cephalalgia, 2016, 36, 371-386.	1.8	148
283	Receiver operating characteristic curve generalization for non-monotone relationships. Statistical Methods in Medical Research, 2017, 26, 113-123.	0.7	18
284	Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine. Cephalalgia, 2017, 37, 356-364.	1.8	27
285	The therapeutic usage of botulinum toxin (Botox) in non-cosmetic head and neck conditions – An evidence based review. Saudi Pharmaceutical Journal, 2017, 25, 18-24.	1.2	40
286	Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. Acta Neurologica Scandinavica, 2017, 135, 476-483.	1.0	32

#	ARTICLE	IF	CITATIONS
287	OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study. <i>Journal of Headache and Pain</i> , 2017, 18, 23.	2.5	23
288	Which Matters More? A Retrospective Cohort Study of Headache Characteristics and Diagnosis Type in Soldiers with mTBI/Concussion. <i>Headache</i> , 2017, 57, 719-728.	1.8	16
289	IncobotulinumtoxinA Injection for Temporomandibular Joint Disorder. <i>Annals of Otology, Rhinology and Laryngology</i> , 2017, 126, 328-333.	0.6	32
290	Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes. <i>Headache</i> , 2017, 57, 766-777.	1.8	40
292	Treatment Update of Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2017, 21, 26.	1.3	37
293	Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Neurology</i> , The, 2017, 16, 425-434.	4.9	589
294	Headache Attributed to Craniocervical Dystonia – A Little Known Headache. <i>Headache</i> , 2017, 57, 336-343.	1.8	13
295	Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies. <i>Headache</i> , 2017, 57, 109-125.	1.8	115
296	Concussion. <i>American Journal of Medicine</i> , 2017, 130, 885-892.	0.6	65
298	Structural Gray Matter Alterations in Chronic Migraine: Implications for a Progressive Disease?. <i>Headache</i> , 2017, 57, 400-416.	1.8	75
299	Similarities and Differences Between Migraine in Children and Adults: Presentation, Disability, and Response to Treatment. <i>Current Pain and Headache Reports</i> , 2017, 21, 48.	1.3	20
300	OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 397-406.	1.5	16
301	Botulinum Toxin Treatment in Multiple Sclerosis – a Review. <i>Current Treatment Options in Neurology</i> , 2017, 19, 33.	0.7	18
302	Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting. <i>Neurological Sciences</i> , 2017, 38, 1779-1789.	0.9	22
303	Sleep in Patients with Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2017, 21, 39.	1.3	45
304	A Critical Evaluation on MOH Current Treatments. <i>Current Treatment Options in Neurology</i> , 2017, 19, 32.	0.7	17
305	Fremanezumab for the Preventive Treatment of Chronic Migraine. <i>New England Journal of Medicine</i> , 2017, 377, 2113-2122.	13.9	573
306	Medication Overuse Headache in the Emergency Department. , 0, , 99-109.		0

#	ARTICLE	IF	CITATIONS
307	CGRP Monoclonal Antibodies for Migraine: Rationale and Progress. <i>BioDrugs</i> , 2017, 31, 487-501.	2.2	45
309	The supraorbital region revisited: An anatomic exploration of the neuro-vascular bundle with regard to frontal migraine headache. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2017, 70, 1171-1180.	0.5	15
310	Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine. <i>Cephalalgia</i> , 2017, 37, 1350-1372.	1.8	31
311	Treatment of chronic daily headache with comorbid anxiety and depression using botulinum toxin A: a prospective pilot study. <i>International Journal of Neuroscience</i> , 2017, 127, 285-290.	0.8	13
312	Strategies for Improving the Efficacy of Treatment of Chronic Migraine. <i>Neuroscience and Behavioral Physiology</i> , 2017, 47, 813-816.	0.2	1
313	Management of Migraine Headaches: OnabotulinumtoxinA Injection. , 2017, , .		0
314	Medikamentöse Schmerztherapie. , 2017, , 391-483.		0
315	The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. <i>Journal of Headache and Pain</i> , 2017, 18, 78.	2.5	34
317	Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. <i>Journal of Headache and Pain</i> , 2017, 18, 101.	2.5	158
319	Orofacial Pain. , 2017, , 1534-1543.		1
320	OnabotulinumtoxinA for Chronic Migraine. <i>Headache</i> , 2017, 57, E10-E16.	1.8	3
321	Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action. <i>Neurotherapeutics</i> , 2018, 15, 313-323.	2.1	73
322	Botulinum toxin: A review of the mode of action in migraine. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 442-451.	1.0	44
323	Commentary on: Effect of Botulinum Toxin A on Muscle Healing and its Implications in Aesthetic and Reconstructive Surgery. <i>Aesthetic Surgery Journal</i> , 2018, 38, 562-564.	0.9	0
324	Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert Review of Neurotherapeutics, 2018, 18, 167-176.	1.4	24
325	Botulinum Toxin Injections for Chronic Pain. , 2018, , 629-633.		0
326	Clinical treatment of chronic and episodic migraine with onabotulinumtoxinA in a real-world setting. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 335-343.	0.3	4
327	An academic debate: OnabotulinumtoxinA for chronic migraine: PREEMPT-derived vs "customized" dosing/injection paradigm. <i>Toxicon</i> , 2018, 147, 116-119.	0.8	3

#	ARTICLE	IF	CITATIONS
328	OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. <i>Drugs</i> , 2018, 78, 589-600.	4.9	50
330	Experiencia con toxina botulnica en la migraa crnica. <i>Neurologa</i> , 2018, 33, 499-504.	0.3	10
331	Headache. <i>American Journal of Medicine</i> , 2018, 131, 17-24.	0.6	85
332	Botulinum toxin for chronic migraine: Clinical trials and technical aspects. <i>Toxicon</i> , 2018, 147, 111-115.	0.8	9
333	Botulinum Toxin Treatment of Migraine and Other Headaches. , 2018, , 145-165.		0
335	A Nursing Intervention Increases Quality of Life and Self-Efficacy in Migraine: A 1-Year Prospective Controlled Trial. <i>Headache</i> , 2018, 58, 260-274.	1.8	17
336	OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. <i>European Journal of Neurology</i> , 2018, 25, 411-416.	1.7	65
337	Role of central versus peripheral opioid system in antinociceptive and anti-inflammatory effect of botulinum toxin type A in trigeminal region. <i>European Journal of Pain</i> , 2018, 22, 583-591.	1.4	28
338	CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study. <i>Headache</i> , 2018, 58, 78-87.	1.8	55
339	Botulinum Toxin for the Treatment of Chronic Migraines. , 2018, , .		1
340	The Role of Botulinum Toxins in Treatment of Headaches. , 2018, , 31-43.		0
341	Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal. <i>Functional Neurology</i> , 2018, 33, 7.	1.3	27
342	Migraine Headache: Updates and Future Developments. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1648-1653.	1.4	15
343	Lifestyle modifications as therapy for medication refractory post-traumatic headache (PTHA) in the military population of Okinawa. <i>Journal of Headache and Pain</i> , 2018, 19, 113.	2.5	11
344	Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. <i>Journal of Headache and Pain</i> , 2018, 19, 121.	2.5	58
346	Emerging drugs for migraine treatment: an update. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 301-318.	1.0	44
347	Comprehensive review and update on chronic migraine. <i>Journal of the Korean Medical Association</i> , 2018, 61, 314.	0.1	1
348	Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. <i>Journal of Headache and Pain</i> , 2018, 19, 91.	2.5	97

#	ARTICLE	IF	CITATIONS
349	Migraine management: beyond pills. <i>British Journal of General Practice</i> , 2018, 68, 464-465.	0.7	1
350	Experience with botulinum toxin in chronic migraine. <i>Neurologia (English Edition)</i> , 2018, 33, 499-504.	0.2	3
351	From LBR-101 to Fremanezumab for Migraine. <i>CNS Drugs</i> , 2018, 32, 1025-1037.	2.7	13
353	12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches. <i>Journal of Headache and Pain</i> , 2018, 19, 80.	2.5	10
354	Chronic Migraine – Evolution of the Concept and Clinical Implications. <i>Headache</i> , 2018, 58, 1495-1500.	1.8	13
355	Chemical Components Separation: Concepts, Evidence, and Outcomes. <i>Plastic and Reconstructive Surgery</i> , 2018, 142, 58S-63S.	0.7	33
356	The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients. <i>Headache</i> , 2018, 58, 973-985.	1.8	10
357	Analgesic Effects of Botulinum Toxins. , 0, , 115-119.		1
358	Botulinum toxins for the prevention of migraine in adults. <i>The Cochrane Library</i> , 2018, 2018, CD011616.	1.5	53
360	OnabotulinumtoxinA in chronic migraine: long-term efficacy in a prophylactic medication free cohort. <i>Neurological Sciences</i> , 2018, 39, 159-160.	0.9	3
361	Migraine Surgery. , 2018, , .		3
362	Chronic Headache Due to Overuse of Analgesics and Anti-Migraine Agents. <i>Deutsches A&#x0308;rztblatt International</i> , 2018, 115, 365-370.	0.6	28
363	Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity. <i>Journal of Neural Transmission</i> , 2018, 125, 1481-1486.	1.4	21
364	Qualitative Change in Migraine Prevention?. <i>Headache</i> , 2018, 58, 1092-1095.	1.8	7
365	Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine. <i>Toxins</i> , 2018, 10, 221.	1.5	11
366	A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience. <i>Acta Neurologica Belgica</i> , 2018, 118, 475-484.	0.5	7
367	The α subunit-containing GABAA receptor: A novel drug target for inhibition of trigeminal activation. <i>Neuropharmacology</i> , 2018, 140, 1-13.	2.0	19
368	Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. <i>Journal of Headache and Pain</i> , 2018, 19, 13.	2.5	126

#	ARTICLE	IF	CITATIONS
369	Does myofascial and trigger point treatment reduce pain and analgesic intake in patients undergoing onabotulinumtoxinA injection due to chronic intractable migraine?. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2018, 54, 1-12.	1.1	24
370	Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives. <i>Cephalalgia</i> , 2018, 38, 1644-1657.	1.8	43
371	Migraine Care Challenges and Strategies in US Uninsured and Underinsured Adults: A Narrative Review, Part 2. <i>Headache</i> , 2018, 58, 633-647.	1.8	10
372	Onabotulinumtoxin A (BOTOX®) for Prophylactic Treatment of Pediatric Migraine: A Retrospective Longitudinal Analysis. <i>Journal of Child Neurology</i> , 2018, 33, 580-586.	0.7	25
373	Headache, Facial Pain, and Disorders of Facial Sensation. , 2019, , 661-684.		1
374	The role of the otolaryngologist in the evaluation and management of headaches. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2019, 40, 115-120.	0.6	14
376	Mechanisms of Botulinum Toxin Type A Action on Pain. <i>Toxins</i> , 2019, 11, 459.	1.5	123
377	Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines. <i>Toxins</i> , 2019, 11, 465.	1.5	6
378	Efficacy and safety of external trigeminal neurostimulation in the prevention of chronic migraine: An open-label trial. <i>Cephalalgia Reports</i> , 2019, 2, 251581631985662.	0.2	6
379	Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. <i>Journal of Headache and Pain</i> , 2019, 20, 84.	2.5	36
380	Consensus of the Brazilian Headache Society on the treatment of chronic migraine. <i>Arquivos De Neuro-Psiquiatria</i> , 2019, 77, 509-520.	0.3	16
381	OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study. <i>Journal of Clinical Neuroscience</i> , 2019, 69, 237-240.	0.8	10
382	Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study. <i>Journal of Headache and Pain</i> , 2019, 20, 81.	2.5	19
383	Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece. <i>Clinical Drug Investigation</i> , 2019, 39, 979-990.	1.1	24
384	Medication Overuse and Medication Overuse Headache: Risk Factors, Comorbidities, Associated Burdens and Nonpharmacologic and Pharmacologic Treatment Approaches. <i>Current Pain and Headache Reports</i> , 2019, 23, 60.	1.3	16
385	Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment. <i>Frontiers in Neurology</i> , 2019, 10, 678.	1.1	35
386	Emerging evidence of occipital nerve compression in unremitting head and neck pain. <i>Journal of Headache and Pain</i> , 2019, 20, 76.	2.5	35
387	Medication-overuse headache. <i>Practical Neurology</i> , 2019, 19, 399-403.	0.5	80

#	ARTICLE	IF	CITATIONS
388	The Role of Onabotulinum Toxin Type A in the Management of Chronic Non-migraine Headaches. <i>Frontiers in Neurology</i> , 2019, 10, 1009.	1.1	3
389	The Use of Botulinum Toxin for Treatment of Depression. <i>Handbook of Experimental Pharmacology</i> , 2019, 263, 265-278.	0.9	6
390	Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine. <i>Headache</i> , 2019, 59, 1743-1752.	1.8	32
392	Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention. <i>Headache</i> , 2019, 59, 1144-1157.	1.8	28
393	Prognosis Following Discontinuation of OnabotulinumA Therapy in "Superresponding" Chronic Migraine Patients. <i>Headache</i> , 2019, 59, 1279-1285.	1.8	12
394	The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials. <i>Brain and Behavior</i> , 2019, 9, e01409.	1.0	39
395	A Prospective Observational Cohort Study on Pharmacological Habitus, Headache-Related Disability and Psychological Profile in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylactic Treatment. <i>Toxins</i> , 2019, 11, 504.	1.5	13
396	Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention. <i>Neurology</i> , 2019, 93, 500-509.	1.5	91
397	Botulinum Toxin Type A in Dental Medicine. <i>Journal of Dental Research</i> , 2019, 98, 1450-1457.	2.5	31
398	Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients. <i>Pain Medicine</i> , 2019, 20, 1815-1821.	0.9	16
399	Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study. <i>Journal of Headache and Pain</i> , 2019, 20, 10.	2.5	18
400	Surgical intervention for chronic migraine headache: A systematic review. <i>JPRAS Open</i> , 2019, 20, 1-18.	0.4	11
401	Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA. <i>European Journal of Neurology</i> , 2019, 26, 1464-1470.	1.7	18
402	Survey of Child Neurologists on Management of Pediatric Post-traumatic Headache. <i>Journal of Child Neurology</i> , 2019, 34, 739-747.	0.7	10
403	Using Functional Near-Infrared Spectroscopy to Study the Effect of Repetitive Transcranial Magnetic Stimulation in Concussion: A Two-Patient Case Study. <i>Frontiers in Neurology</i> , 2019, 10, 476.	1.1	16
404	Transcutaneous Supraorbital Stimulation as a Preventive Treatment for Chronic Migraine: A Prospective, Open-Label Study. <i>Pain Medicine</i> , 2020, 21, 415-422.	0.9	10
405	Pathophysiology, prevention, and treatment of medication overuse headache. <i>Lancet Neurology</i> , The, 2019, 18, 891-902.	4.9	151
406	Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 769-776.	1.4	22

#	ARTICLE	IF	CITATIONS
407	Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data. <i>Cephalalgia</i> , 2019, 39, 945-956.	1.8	29
409	Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. <i>Cephalalgia</i> , 2019, 39, 931-944.	1.8	27
410	OnabotulinumtoxinA for Refractory Headache. <i>Headache</i> , 2019, , 45-54.	0.2	0
411	Traditional and Novel Migraine Therapy in the Aging Population. <i>Current Pain and Headache Reports</i> , 2019, 23, 42.	1.3	5
412	Erenumab in chronic migraine with medication overuse. <i>Neurology</i> , 2019, 92, e2309-e2320.	1.5	163
413	Erenumab in chronic migraine. <i>Neurology</i> , 2019, 92, e2250-e2260.	1.5	83
414	Fremanezumab as a preventive treatment for episodic and chronic migraine. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 719-728.	1.4	12
415	Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. <i>Brain</i> , 2019, 142, 1203-1214.	3.7	68
416	Development of an education and self-management intervention for chronic headache â€” CHES trial (Chronic Headache Education and Self-management Study). <i>Journal of Headache and Pain</i> , 2019, 20, 28.	2.5	19
417	Prediction of patient's response to OnabotulinumtoxinA treatment for migraine. <i>Heliyon</i> , 2019, 5, e01043.	1.4	15
418	TRP Channels and Migraine: Recent Developments and New Therapeutic Opportunities. <i>Pharmaceuticals</i> , 2019, 12, 54.	1.7	68
419	Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences. <i>Quality of Life Research</i> , 2019, 28, 2359-2372.	1.5	15
420	Headaches in Idiopathic Intracranial Hypertension. <i>Journal of Neuro-Ophthalmology</i> , 2019, 39, 82-93.	0.4	27
421	Intraoral Administration of Botulinum Toxin for Continuous Dentoalveolar Neuropathic Pain: A Case Series. <i>Journal of Oral and Facial Pain and Headache</i> , 2019, 33, 160-164.	0.7	5
422	Mujer con cefalea de larga evoluci3n y m4ltiples s4ntomas acompa±antes. <i>Medicine</i> , 2019, 12, 4203.e1-4203.e4.	0.0	0
423	Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study. <i>Journal of Headache and Pain</i> , 2019, 20, 12.	2.5	16
425	What's New in the Treatment of Migraine?. <i>Journal of Neuro-Ophthalmology</i> , 2019, 39, 352-359.	0.4	19
426	Ultrasound-Guided Perisutural Botulinum Toxin Injection for Chronic Migraine Headache. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2019, 98, e98-e100.	0.7	4

#	ARTICLE	IF	CITATIONS
427	Pharmacologic Approaches to CDH: Evidence and Outcomes. , 2019, , 217-230.		0
428	Neurostimulation in the Management of Chronic Migraine. , 2019, , 335-344.		0
429	A Critical Review of Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Migraine in Adults. Aesthetic Surgery Journal, 2019, 39, 898-907.	0.9	4
430	Chronic Migraine: Epidemiology, Mechanisms, and Treatment. , 2019, , 37-62.		1
431	Medication Overuse in Chronic Daily Headache. , 2019, , 195-206.		0
432	Botulinum toxin in women's health: An update. Maturitas, 2019, 119, 21-24.	1.0	5
433	Botulinum toxin in the management of myofascial pain associated with temporomandibular dysfunction. Journal of Oral Pathology and Medicine, 2019, 48, 192-200.	1.4	16
434	Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. Cephalalgia, 2019, 39, 608-616.	1.8	17
435	Evidencia y experiencia del uso de onabotulinumtoxinA en neuralgia del trigémino y cefaleas primarias distintas de la migraña crónica. Neurología, 2020, 35, 568-578.	0.3	12
436	Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK. Journal of Medical Economics, 2020, 23, 113-123.	1.0	12
437	Neuromodulation in Headache and Facial Pain Management. Headache, 2020, , .	0.2	9
438	Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine. Headache, 2020, 60, 153-161.	1.8	7
439	Migraine: a brain state amenable to therapy. Medical Journal of Australia, 2020, 212, 32-39.	0.8	8
440	The Burden of Migraine in Real Clinical Practice: Clinical and Economic Aspects. Neuroscience and Behavioral Physiology, 2020, 50, 20-26.	0.2	2
441	Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine. Brain, 2020, 143, e6-e6.	3.7	2
442	No "Wearing-Off" Effect Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study. Headache, 2020, 60, 2431-2443.	1.8	19
443	Effectiveness, Safety, and Health-Related Quality of Life of Chronic Migraine Patients Treated with Onabotulinum Toxin A. European Neurology, 2020, 83, 517-522.	0.6	3
444	OnabotulinumtoxinA injection in the treatment of chronic migraine. Progress in Brain Research, 2020, 255, 171-206.	0.9	6

#	ARTICLE	IF	CITATIONS
445	Anatomical guide for botulinum neurotoxin injection: Application to cosmetic shoulder contouring, pain syndromes, and cervical dystonia. <i>Clinical Anatomy</i> , 2021, 34, 822-828.	1.5	23
446	Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis. <i>Pain and Therapy</i> , 2020, 9, 683-694.	1.5	3
447	Clinician-Patient Dialogue About Preventive Chronic Migraine Treatment. <i>Journal of Primary Care and Community Health</i> , 2020, 11, 215013272095993.	1.0	4
449	What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1275-1286.	1.4	14
450	Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis. <i>Headache</i> , 2020, 60, 1542-1557.	1.8	32
451	Periorbital botulinum toxin A improves photophobia and sensations of dryness in patients without migraine: Case series of four patients. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 19, 100809.	0.4	14
452	Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. <i>Journal of Headache and Pain</i> , 2020, 21, 88.	2.5	25
453	Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. <i>Headache</i> , 2020, 60, 2220-2231.	1.8	34
454	OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients. <i>Journal of Headache and Pain</i> , 2020, 21, 129.	2.5	30
455	Cognitive effects of onabotulinumtoxinA in chronic migraine. <i>BMJ Neurology Open</i> , 2020, 2, e000014.	0.7	2
456	Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites. <i>Scientific Reports</i> , 2020, 10, 12851.	1.6	18
457	A Comprehensive Review of Surgical Treatment of Migraine Surgery Safety and Efficacy. <i>Plastic and Reconstructive Surgery</i> , 2020, 146, 187e-195e.	0.7	17
458	Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine. <i>Toxins</i> , 2020, 12, 479.	1.5	12
459	Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway. <i>Journal of Headache and Pain</i> , 2020, 21, 99.	2.5	15
460	Toxine botulique de type A et migraine chronique: une revue des données récentes. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2020, 204, 386-392.	0.0	0
461	The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine. <i>Pain and Therapy</i> , 2020, 9, 695-707.	1.5	3
462	Response to Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice. <i>Headache</i> , 2020, 60, 2597-2599.	1.8	3
463	Effect of circadian rhythm on the pain associated with preventive onabotulinumtoxinA injections for migraines. <i>Chronobiology International</i> , 2020, 37, 1766-1771.	0.9	4

#	ARTICLE	IF	CITATIONS
464	Botulinum Toxin for Headache: a Comprehensive Review. <i>Current Otorhinolaryngology Reports</i> , 2020, 8, 369-377.	0.2	0
467	Wearâ€œOff of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries. <i>Headache</i> , 2020, 60, 1673-1682.	1.8	12
468	Role of greater occipital nerve block for preventive treatment of chronic migraine: A critical review. <i>Cephalalgia Reports</i> , 2020, 3, 251581632096440.	0.2	5
469	Botulinum Toxin in the Treatment of Headache. <i>Toxins</i> , 2020, 12, 803.	1.5	29
470	OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use. <i>CNS Drugs</i> , 2020, 34, 1287-1298.	2.7	7
471	Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine. <i>NeurologÃa (English Edition)</i> , 2020, 35, 568-578.	0.2	0
472	Effects of Procedural Discomfort and Expectation of Benefit on Therapy Continuation in Chronic Migraine Patients Treated With OnabotulinumtoxinA. <i>Headache</i> , 2020, 60, 2357-2363.	1.8	0
473	Hospital-based headache care during the Covid-19 pandemic in Denmark and Norway. <i>Journal of Headache and Pain</i> , 2020, 21, 128.	2.5	21
474	Delay in OnabotulinumtoxinA Treatment During the COVIDâ€œ19 Pandemicâ€œPerspectives from a Virus Hotspot. <i>Headache</i> , 2020, 60, 1183-1186.	1.8	18
475	Onabotulinumtoxin Type A reconstitution with preserved versus preservativeâ€œfree saline in chronic migraine (Bâ€œRECON). A randomised, doubleâ€œblind trial. <i>International Journal of Clinical Practice</i> , 2020, 74, e13522.	0.8	3
476	Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: the PREVENBOX study. <i>European Journal of Neurology</i> , 2020, 27, 2102-2108.	1.7	4
477	European Academy of Neurology guideline on the management of medicationâ€œoveruse headache. <i>European Journal of Neurology</i> , 2020, 27, 1102-1116.	1.7	69
478	Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study. <i>Frontiers in Neurology</i> , 2020, 11, 417.	1.1	59
479	Update in migraine preventive treatment. <i>Progress in Brain Research</i> , 2020, 255, 1-27.	0.9	4
480	The Use of Botulinum Toxin in the Management of Headache Disorders. <i>Handbook of Experimental Pharmacology</i> , 2020, 263, 227-249.	0.9	5
481	Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions. <i>Neurology and Therapy</i> , 2020, 9, 117-133.	1.4	4
483	Digital Cognitive Behavioral Therapy for Insomnia in Women With Chronic Migraines. <i>Headache</i> , 2020, 60, 902-915.	1.8	24
484	Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review. <i>Headache</i> , 2020, 60, 1259-1272.	1.8	95

#	ARTICLE	IF	CITATIONS
485	The Efficacy of Botulinum Toxin in Pediatric Chronic Migraine: A Literature Review. <i>Journal of Child Neurology</i> , 2020, 35, 844-851.	0.7	11
486	Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients. <i>Scientific Reports</i> , 2020, 10, 11382.	1.6	6
487	Botulinum Toxin and Pain. <i>Handbook of Experimental Pharmacology</i> , 2020, 263, 251-264.	0.9	14
488	A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine. <i>Headache</i> , 2020, 60, 564-575.	1.8	30
489	New analgesic: Focus on botulinum toxin. <i>Toxicon</i> , 2020, 179, 1-7.	0.8	8
490	Migraine Treatment. <i>Clinics in Plastic Surgery</i> , 2020, 47, 295-303.	0.7	14
491	Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study. <i>Headache</i> , 2020, 60, 677-685.	1.8	15
493	Botulinum Neurotoxins and Cancer? A Review of the Literature. <i>Toxins</i> , 2020, 12, 32.	1.5	28
494	Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice. <i>Headache</i> , 2020, 60, 1365-1375.	1.8	10
495	Chronic migraine and Botulinum Toxin Type A: Where do paths cross?. <i>Toxicon</i> , 2020, 178, 69-76.	0.8	12
496	The Many Faces of Medication-Overuse Headache in Clinical Practice. <i>Headache</i> , 2020, 60, 1021-1036.	1.8	9
497	Medication-overuse headache: painkillers are not always the answer. <i>British Journal of General Practice</i> , 2020, 70, 58-59.	0.7	3
498	Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data. <i>Journal of Headache and Pain</i> , 2020, 21, 40.	2.5	22
499	Documento de revisión y actualización de la cefalea por uso excesivo de medicación (CUEM). <i>Neurología</i> , 2021, 36, 229-240.	0.3	5
500	Botulinum Toxin Type A for the Treatment of Post-traumatic Headache: A Randomized, Placebo-Controlled, Cross-over Study. <i>Military Medicine</i> , 2021, 186, 493-499.	0.4	14
501	Reversion from chronic migraine to episodic migraine: A new outcome measure. <i>Cephalalgia</i> , 2021, 41, 3-5.	1.8	0
502	Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine. <i>Neurotherapeutics</i> , 2021, 18, 556-568.	2.1	8
503	Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 study. <i>Quality of Life Research</i> , 2021, 30, 931-943.	1.5	14

#	ARTICLE	IF	CITATIONS
504	Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2021, 35, 1-6.	0.5	32
505	Mild systemic inflammation enhances response to OnabotulinumtoxinA in chronic migraineurs. <i>Scientific Reports</i> , 2021, 11, 1092.	1.6	5
506	Prophylaxis of Migraine Protocols and Options. , 2021, , 51-73.		0
507	Long term outcome for onabotulinumtoxinA (Botox) therapy in chronic migraine: A 2-year prospective follow-up audit of patients attending the Hull (UK) migraine clinic. <i>Cephalalgia Reports</i> , 2021, 4, 251581632098544.	0.2	2
508	Onabotulinumtoxin A Improves Psychological Aspects in Chronic Migraine Patients. <i>Frontiers in Neurology</i> , 2020, 11, 633355.	1.1	1
510	Comprehensive management of adults with chronic migraine: Clinical practice guidelines in Mexico. <i>Cephalalgia Reports</i> , 2021, 4, 251581632110339.	0.2	0
512	Experience of Botulinum Toxin A Injections for Chronic Migraine Headaches in a Pediatric Chronic Pain Clinic. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2021, 26, 151-156.	0.3	3
513	Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis. <i>Cephalalgia</i> , 2021, 41, 851-864.	1.8	53
514	Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. <i>Pain and Therapy</i> , 2021, 10, 637-650.	1.5	12
515	Combined Interventional Treatment of Refractory Chronic Migraine. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1320-1326.	0.3	4
516	Medication overuse headache. <i>Current Opinion in Neurology</i> , 2021, 34, 378-383.	1.8	4
517	The effectiveness of propranolol, flunarizine, amitriptyline and botulinum toxin in vestibular migraine complaints and prophylaxis: a non-randomized controlled study. <i>Brazilian Journal of Otorhinolaryngology</i> , 2022, 88, 975-981.	0.4	8
518	Structural brain network characteristics in patients with episodic and chronic migraine. <i>Journal of Headache and Pain</i> , 2021, 22, 8.	2.5	7
519	Headache secondary to cerebrovascular disease. <i>Cephalalgia</i> , 2021, 41, 479-492.	1.8	2
520	Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: A real-world evidence study. <i>European Journal of Neurology</i> , 2021, 28, 2378-2382.	1.7	17
521	Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review. <i>Pain and Therapy</i> , 2021, 10, 809-826.	1.5	49
522	Document of revision and updating of medication overuse headache (MOH). <i>Neurologia (English)</i> Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.2	1
523	The use of onabotulinumtoxin A in migraine: mechanism of action, efficacy, safety and tolerability. <i>Journal of Aesthetic Nursing</i> , 2021, 10, 98-103.	0.0	1

#	ARTICLE	IF	CITATIONS
524	Clinical and Neurophysiological Effects of Botulinum Neurotoxin Type A in Chronic Migraine. <i>Toxins</i> , 2021, 13, 392.	1.5	6
525	Systemic muscular weakness after botulinum toxin A administration: a review of the literature. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 315-327.	0.3	1
526	Botulinum toxin A in Patients with Chronic Migraine: A Single-Center Experience;. <i>Journal of Contemporary Medicine</i> , 2021, 11, 272-276.	0.1	0
527	The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update. <i>CNS Drugs</i> , 2021, 35, 545-565.	2.7	25
528	Calcitonin Gene-Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison. <i>Frontiers in Pharmacology</i> , 2021, 12, 631204.	1.6	11
529	Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). <i>Journal of Headache and Pain</i> , 2021, 22, 35.	2.5	82
530	The efficacy of botulinum toxin type-A for intractable chronic migraine patients with no pain-free time. <i>British Journal of Pain</i> , 2022, 16, 41-49.	0.7	4
531	OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy. <i>Journal of Clinical Medicine</i> , 2021, 10, 2898.	1.0	13
532	Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. <i>Headache</i> , 2021, 61, 992-1003.	1.8	44
533	Clinic-based Procedures for Headache. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2021, 27, 732-745.	0.4	1
534	Safety and Efficacy of 10 kHz Spinal Cord Stimulation for the Treatment of Refractory Chronic Migraine: A Prospective Long-Term Open-Label Study. <i>Neuromodulation</i> , 2022, 25, 103-113.	0.4	9
535	Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA. <i>Toxins</i> , 2021, 13, 432.	1.5	5
536	Approach to Pediatric Intractable Migraine. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 38.	2.0	2
537	OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 540-552.	0.3	5
538	OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-15.	1.0	10
539	Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. <i>Journal of Headache and Pain</i> , 2021, 22, 81.	2.5	11
540	Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 923-944.	1.4	12
541	Percutaneous Interventional Strategies for Migraine Prevention: A Systematic Review and Practice Guideline. <i>Pain Medicine</i> , 2022, 23, 164-188.	0.9	11

#	ARTICLE	IF	CITATIONS
542	Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives. <i>Frontiers in Pain Research</i> , 2021, 2, 705276.	0.9	31
543	Instrumental assessment of physiotherapy and onabotulinumtoxin-A on cervical and headache parameters in chronic migraine. <i>Neurological Sciences</i> , 2022, 43, 2021-2029.	0.9	10
544	BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm. <i>Cephalalgia</i> , 2022, 42, 170-175.	1.8	7
545	Intra-arterial injection of lidocaine into middle meningeal artery to treat intractable headaches and severe migraine. <i>Journal of Neuroimaging</i> , 2021, 31, 1126-1134.	1.0	4
546	Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1157-1170.	0.5	4
547	Botulinum toxin type A wear-off phenomenon in chronic migraine patients: how long does the maximum efficiency last?. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 886-890.	0.3	4
548	A Qualitative Study to Explore Patient Perspectives of Prophylactic Treatment with OnabotulinumtoxinA for Chronic Migraine. <i>Pain and Therapy</i> , 2021, 10, 1523-1536.	1.5	3
549	Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients. <i>Pain and Therapy</i> , 2021, 10, 1605-1618.	1.5	8
550	Analgesic potential of different available commercial brands of botulinum neurotoxin-A in formalin-induced orofacial pain in mice. <i>Toxicon: X</i> , 2021, 12, 100083.	1.2	0
551	Does cognitive dysfunction correlate with dizziness severity in patients with vestibular migraine?. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021, 42, 103124.	0.6	10
552	tVNS in the management of headache and pain. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2021, 236, 102875.	1.4	9
553	Migraine and Stroke. , 2022, , 604-614.e4.		0
554	The Role of Botulinum Toxin in Facial Palsy Management. , 2022, , 39-50.		1
556	Comparing the Efficacy, Safety, and Superiority of Calcitonin Gene-Related Peptide Monoclonal Antibodies and Botox in Preventing and Treating Migraines. <i>Cureus</i> , 2021, 13, e13002.	0.2	7
557	Clinical and Cost Effectiveness of Neuromodulation Devices in the Treatment of Headaches: Focus on Non-invasive Therapies. <i>Headache</i> , 2020, , 241-257.	0.2	2
558	Placebo and Nocebo Effects. <i>Headache</i> , 2016, , 31-43.	0.2	1
559	Factors implicated in response to treatment/prognosis of vestibular migraine. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 57-66.	0.8	11
560	Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial. <i>Neurological Sciences</i> , 2017, 38, 201-206.	0.9	50

#	ARTICLE	IF	CITATIONS
561	Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy. <i>Neurological Sciences</i> , 2020, 41, 1809-1820.	0.9	13
562	Headache and Other Craniofacial Pain. , 2012, , 1703-1744.		7
563	Medikamentöse Schmerztherapie. , 2011, , 337-399.		2
565	Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population. <i>Headache</i> , 2021, 61, 373-384.	1.8	3
566	Effectiveness of onabotulinumtoxinA (BOTOX) in pediatric patients experiencing migraines: a randomized, double-blinded, placebo-controlled crossover study in the pediatric pain population. <i>Regional Anesthesia and Pain Medicine</i> , 2021, 46, 41-48.	1.1	21
567	Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. <i>Clinical and Translational Neuroscience</i> , 2019, 3, 2514183X1882337.	0.4	41
571	A Review of the Potential Receptors of Migraine with a Special Emphasis on CGRP to Develop an Ideal Antimigraine Drug. <i>Current Molecular Pharmacology</i> , 2020, 14, 11-26.	0.7	6
572	Low-dosed Botulinum Toxin A in the Prophylactic Management of Unilateral Migraine: A Randomized Double-blind Placebo-Controlled Crossover Study. <i>Open Pain Journal</i> , 2011, 4, 4-7.	0.4	4
574	Migraine - from pathophysiology to monoclonal antibodies. <i>Neurologie Pro Praxi</i> , 2019, 20, 296-300.	0.0	3
575	CGRP monoclonal antibodies for migraine prophylaxis. <i>Neurologie Pro Praxi</i> , 2019, 20, 356-360.	0.0	2
576	OnabotulinumtoxinA Nerve Blocks in the Treatment of Occipital Neuralgia. <i>Pain Studies and Treatment</i> , 2016, 04, 29-34.	0.3	1
577	Recent updates on treatment for pediatric migraine. <i>Journal of the Korean Medical Association</i> , 2017, 60, 118.	0.1	4
578	Beyond Beauty: Onabotulinumtoxin A (BOTOX®) and the Management of Migraine Headaches. <i>Anesthesiology and Pain Medicine</i> , 2012, 2, 5-11.	0.5	19
579	Current Evidence in Migraine Surgery. <i>Annals of Plastic Surgery</i> , 2022, 89, 113-120.	0.5	4
580	CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. <i>Journal of Headache and Pain</i> , 2021, 22, 128.	2.5	66
581	Increased migraine-free intervals with multifocal repetitive transcranial magnetic stimulation. <i>Brain Stimulation</i> , 2021, 14, 1544-1552.	0.7	7
583	Medical Interventions for Migraine That Has Become Difficult to Treat. , 2011, , 423-434.		0
584	Migración con y sin aura. Tratamiento. , 2011, , 83-106.		1

#	ARTICLE	IF	CITATIONS
585	AntimigraÃ±osos. , 2011, , 169-190.		0
586	Treatment and Prevention of Migraine. , 2011, , 255-263.		0
591	MigrÃ±e. , 2012, , 17-348.		0
593	MigrÃ±e. , 2012, , 145-381.		1
594	Loosening the grip of migraine attacks. Pharmacy Today, 2012, 18, 61-72.	0.0	0
598	Botulinum toxins in the treatment of dystonia. , 2012, , 413-435.		0
600	Case report : Anterior Open bite after injection of Botulinum Toxin on Masseter Muscles. Journal of Oral Medicine and Pain, 2013, 38, 325-331.	0.2	1
602	IncobotulinumtoxinA (XeominÂ®) and OnabotulinumtoxinA (BotoxÂ®) for Chronic Migraine Headache: Experience with Higher Doses and Changes to the Injection Technique. Journal of Neurological Disorders, 2014, 02, .	0.1	1
603	Botulinum Neurotoxins as Therapeutics. , 2014, , 553-590.		0
605	Onabotulinum Toxin Injection and Headaches. , 2014, , 103-110.		0
606	Kopfschmerzen. , 2014, , 1247-1252.		0
607	Clinical Use of Botulinum Neurotoxins: Pain. , 2014, , 153-176.		0
608	Refractory Chronic Migraine Therapy with Botulinum Toxin A. Headache, 2015, , 35-43.	0.2	0
611	Migraine and Other Primary Headaches. , 2015, , 49-67.		0
612	The Effect of Onabotulinum Toxin-A on Frequency of Headache, Severity of Headache and Health Related Life-Quality at Patients With Resistant Chronic Migraine. Neurological Sciences and Neurophysiology, 2015, , .	0.1	0
613	OnabotulinumtoxinA in the Treatment of Occipital Neuralgia Following Gunshot Injury. Pain Studies and Treatment, 2016, 04, 43-47.	0.3	1
614	Pharmacological Strategies in the Prevention of Migraine in Children. Headache, 2016, , 145-154.	0.2	0
615	Drug Treatment for Chronic Migraine. Headache, 2016, , 81-87.	0.2	0

#	ARTICLE	IF	CITATIONS
616	Kopfschmerz bei Medikamenten-Mißgebrauch. , 2017, , 503-518.		0
618	Botulinum toxin type A for the migraine prophylactic treatment Botulinum toxin type A for the migraine prophylactic treatment. Neurologie Pro Praxi, 2017, 18, 117-120.	0.0	0
619	Botulinum Toxin Treatment in Multiple Sclerosis. , 2018, , 109-129.		0
620	Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders. Noropsikiyatri Arsivi, 2018, 55, 330-336.	0.2	2
622	Chirurgische Therapie von Kopfschmerzen. , 2018, , 229-266.		0
623	Primary headaches - treatment today and tomorrow. Neurologie Pro Praxi, 2018, 19, 193-198.	0.0	1
624	Migraine in primary care: myths, management and medication overuse. Primary Health Care, 2018, 28, 38-49.	0.0	0
625	The organizations of specialized medical care for patients with headache. Journal of Clinical Practice, 2019, 10, 108-113.	0.2	1
627	Expected future developments in child neurology. Journal of International Child Neurology Association, 0, , .	0.0	0
632	Types of Toxins in Commercial Use, Their Similarities and Differences. , 2020, , 27-41.		0
633	Use of Botulinum Toxin A in Postmastectomy Breast Reconstruction. , 2020, , 187-193.		1
634	Chronic Migraine. , 0, , .		0
635	Effectiveness of preventive onabotulinumtoxin A injections for migraine headaches is dependent on the circadian time of administration. Chronobiology International, 2021, 38, 576-583.	0.9	1
636	Chronic Migraine in Adolescence. , 0, , .		1
637	Medication Overuse Headache. , 0, , .		0
638	Nummular Headache. , 2020, , 119-125.		0
639	Pathophysiology and Diagnosis of Nerve Compression Headache. , 2020, , 1-13.		0
642	The Story of Migraine Surgery: 20 Years in the Making. , 2020, , 195-201.		0

#	ARTICLE	IF	CITATIONS
645	Botulinum Toxin Therapy in Medical Pain Disorders. , 2020, , 131-156.		0
646	Interventional Treatment of Chronic Pain. , 2021, , 113-128.		0
648	Chronic migraine - new treatment options. MÃ dica, 2014, 9, 401-4.	0.4	1
649	Migraine management. Australian Prescriber, 2020, 43, 148-151.	0.5	0
650	Preventive injections: onabotulinum toxin A and nerve blocks. , 2022, , 181-190.		0
651	An Update on Diagnosis and Pharmacologic Therapy for Headache in the Oral and Maxillofacial Surgery Practice. Oral and Maxillofacial Surgery Clinics of North America, 2022, 34, 83-97.	0.4	0
652	Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3â€month observational, longitudinal, cohort, multicenter, Italian realâ€life study. European Journal of Neurology, 2022, 29, 1198-1208.	1.7	43
653	Migraine management. Australian Prescriber, 2020, 43, 148-151.	0.5	7
654	BLOQUEIO NERVOSO PERIFÃ%RICO COMO TRATAMENTO CIRÃŠRGICO PARA DOR DE CABEÃ†A DE USO EXCESSIVO DE MEDICAMENTOS: DOIS RELATÃ“RIOS DE CASO. Recisatec, 2022, 2, e2173.	0.0	0
656	NGF Enhances CGRP Release Evoked by Capsaicin from Rat Trigeminal Neurons: Differential Inhibition by SNAP-25-Cleaving Proteases. International Journal of Molecular Sciences, 2022, 23, 892.	1.8	5
657	Migraine. Nature Reviews Disease Primers, 2022, 8, 2.	18.1	154
658	The evolving classifications and epidemiological challenges surrounding chronic migraine and medication overuse headache: a review. Korean Journal of Pain, 2022, 35, 4-13.	0.8	3
659	Comparative Effectiveness of Landmark-guided Greater Occipital Nerve (GON) Block at the Superior Nuchal Line Versus Ultrasound-guided GON Block at the Level of C2. Clinical Journal of Pain, 2022, 38, 271-278.	0.8	6
660	Botulinum Neurotoxin Chimeras Suppress Stimulation by Capsaicin of Rat Trigeminal Sensory Neurons In Vivo and In Vitro. Toxins, 2022, 14, 116.	1.5	5
661	Botulinum Toxin Type A Satisfaction in Different Neurological Disorders. Neuroscience and Medicine, 2022, 13, 1-16.	0.2	0
662	Sex Differences in Chronic Migraine: Focusing on Clinical Features, Pathophysiology, and Treatments. Current Pain and Headache Reports, 2022, 26, 347-355.	1.3	14
663	FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for chronic migraine. Cephalalgia, 2022, 42, 590-597.	1.8	7
664	Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial. Cephalalgia, 2022, 42, 859-871.	1.8	8

#	ARTICLE	IF	CITATIONS
665	New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3018.	1.8	4
666	Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review. <i>Pain Research and Management</i> , 2022, 2022, 1-15.	0.7	10
667	Refractory Chronic Migraine. , 2022, , 129-134.		0
668	BOTULINUM. <i>Health and Society</i> , 2022, 2, .	0.0	0
669	Effects of onabotulinumtoxin A in patients concurrently diagnosed with chronic migraine encephalalgia and temporomandibular disorders: A retrospective case series. <i>Cranio - Journal of Craniomandibular Practice</i> , 2022, , 1-11.	0.6	0
670	Impact of botulinum toxin injection into the masticatory muscles on mandibular bone: A systematic review. <i>Journal of Oral Rehabilitation</i> , 2022, 49, 644-653.	1.3	6
671	Generalized Anxiety Disorder: A Predictor for Poor Responsiveness to Botulinum Toxin Type A Therapy for Pediatric Migraine. <i>Pediatric Neurology</i> , 2022, 130, 21-27.	1.0	2
672	Treating chronic migraines with botulinum toxin. <i>Journal of Aesthetic Nursing</i> , 2021, 10, 440-444.	0.0	0
673	Comprehensive approach for the treatment of medication-overuse headache. <i>Journal of the Korean Medical Association</i> , 2021, 64, 843-851.	0.1	0
674	Increase in ACC GABA+ levels correlate with decrease in migraine frequency, intensity and disability over time. <i>Journal of Headache and Pain</i> , 2021, 22, 150.	2.5	9
676	Impact of Greater Occipital Nerve Block on Photophobia Levels in Migraine Patients. <i>Journal of Neuro-Ophthalmology</i> , 2022, Publish Ahead of Print, .	0.4	1
677	Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence. <i>European Journal of Neurology</i> , 2022, 29, 2473-2480.	1.7	9
678	OnabotulinumtoxinA Reduces Health Resource Utilization in Chronic Migraine: PREDICT Study. <i>Canadian Journal of Neurological Sciences</i> , 2022, , 1-35.	0.3	1
679	Is Botox Right for Me: When to Assess the Efficacy of the Botox Injection for Chronic Migraine in Pediatric Population. <i>Neuropediatrics</i> , 2022, 53, 344-350.	0.3	4
680	Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER). <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, , 1-12.	0.5	3
681	Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis. <i>Toxins</i> , 2022, 14, 296.	1.5	3
682	Differences in Botulinum Toxin Injection Into Temporal Muscles in Sleep Bruxism and Chronic Migraine. <i>Sleep Medicine Research</i> , 0, , .	0.2	0
683	Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache. <i>Cephalalgia</i> , 2022, , 033310242210998.	1.8	3

#	ARTICLE	IF	CITATIONS
688	Botulinum toxin type A for lower limb lengthening and deformity correction: A systematic review and meta-analysis. <i>Journal of Orthopaedic Science</i> , 2023, 28, 806-813.	0.5	2
689	Subcutaneous BoNT/A Injection for Intractable Pain and Disability in Complex Regional Pain Syndrome: A Case Report. <i>Toxins</i> , 2022, 14, 411.	1.5	4
690	OnabotulinumtoxinA in chronic migraine: is the response dose dependent?. <i>BMC Neurology</i> , 2022, 22, .	0.8	2
691	Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine. <i>Expert Opinion on Pharmacotherapy</i> , 0, , 1-11.	0.9	2
692	Guidelines for Botulinum Neurotoxin Injection for Facial Contouring. <i>Plastic and Reconstructive Surgery</i> , 2022, 150, 562e-571e.	0.7	21
693	Prospective Comparison of Longer Needle Lengths to Assess the Risk of OnabotulinumtoxinA-Associated Neck Pain in Patients with Chronic Migraine. <i>Toxins</i> , 2022, 14, 434.	1.5	3
694	Local Anesthetic Therapy in a Patient with Primary Headache and Lipid Keratopathy. <i>Medica Review</i> , 2022, 10, .	0.1	0
695	Migraine management: an update for the 2020s. <i>Internal Medicine Journal</i> , 2022, 52, 1123-1128.	0.5	4
696	Safety of OnabotulinumtoxinA in the [management of] chronic migraine in pregnancy. <i>Frontiers in Pain Research</i> , 0, 3, .	0.9	1
697	Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine. <i>Toxins</i> , 2022, 14, 529.	1.5	15
698	Increasing Collaboration between Headache Medicine and Plastic Surgery in the Surgical Management of Chronic Headache. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2022, 10, e4479.	0.3	4
700	New Oral Drugs for Migraine. <i>CNS Drugs</i> , 2022, 36, 933-949.	2.7	11
701	Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data. <i>Cephalalgia</i> , 2022, 42, 1543-1564.	1.8	12
702	Primary Care-Based Interventional Procedures for Chronic Pain. <i>Primary Care - Clinics in Office Practice</i> , 2022, 49, 425-437.	0.7	2
703	Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine. <i>Current Medical Research and Opinion</i> , 2023, 39, 105-112.	0.9	2
704	Headache in the Pediatric Population: Focus on Migraine. <i>Seminars in Neurology</i> , 2022, 42, 479-488.	0.5	0
705	Chronic Migraine. <i>Neurologic Clinics</i> , 2023, 41, 141-159.	0.8	5
706	Migraine research comes of age in the 21st century. <i>Lancet Neurology</i> , The, 2022, 21, 955-958.	4.9	4

#	ARTICLE	IF	CITATIONS
707	Impacts of the preempt protocol on chronic migraine: an integrative review. <i>Headache Medicine</i> , 2022, 13, 179-185.	0.1	0
708	Prevention of Migraine. <i>Seminars in Neurology</i> , 2022, 42, 558-570.	0.5	0
709	OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine. <i>Toxins</i> , 2022, 14, 847.	1.5	16
710	Dual therapy with Erenumab and onabotulinumtoxinA: No synergistic effect in chronic migraine: A retrospective cohort study. <i>Pain Practice</i> , 2023, 23, 349-358.	0.9	1
711	Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study. <i>Toxins</i> , 2022, 14, 850.	1.5	2
712	Meta-Analysis of Effectiveness and Safety of Botulinum Toxin in the Treatment of Complex Regional Pain Syndrome. <i>Life</i> , 2022, 12, 2037.	1.1	1
714	OnabotulinumtoxinA: Still the Present for Chronic Migraine. <i>Toxins</i> , 2023, 15, 59.	1.5	4
716	Bipartite Activation of Sensory Neurons by a TRPA1 Agonist Allyl Isothiocyanate Is Reflected by Complex Ca ²⁺ Influx and CGRP Release Patterns: Enhancement by NGF and Inhibition with VAMP and SNAP-25 Cleaving Botulinum Neurotoxins. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1338.	1.8	2
717	OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity. <i>Toxins</i> , 2023, 15, 29.	1.5	2
718	Results of a Web-Based Survey on 2105 Greek Migraine Patientsâ€™ Second Part: Efficacy of Acute and Prophylactic Migraine Treatments and Corresponding Patientsâ€™ Reported Satisfaction. <i>Medicina (Lithuania)</i> , 2023, 59, 31.	0.8	1
719	Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine. <i>CNS Drugs</i> , 2023, 37, 189-202.	2.7	1
720	The sense of stopping migraine prophylaxis. <i>Journal of Headache and Pain</i> , 2023, 24, .	2.5	8
722	Efficacy and safety of two different botulinum toxin type A dilutions in chronic migraineurs. <i>Toxicon</i> , 2023, 227, 107096.	0.8	1
723	Assessing change in functional outcomes and quality of life in myogenic temporomandibular disorders undergoing botulinum toxin injection: A before and after comparison. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2023, 124, 101434.	0.5	0
724	Future of Pediatric Headache: Where Do We Go from Here?. , 2022, , 191-196.		0
725	Three men in a boat: The comparison of the combination therapy of botulinum toxin and greater occipital nerve block with bupivacaine, with botulinum toxin monotherapy in the management of chronic migraine. <i>Clinical Neurology and Neurosurgery</i> , 2023, 226, 107609.	0.6	1
726	Medication-overuse Headache: Diagnostic Criteria, Epidemiology, and Treatment. <i>Journal of the Korean Neurological Association</i> , 2023, 41, 1-10.	0.0	1
727	Greater occipital nerve blockade for the preventive treatment of chronic migraine: A randomized double-blind placebo-controlled study. <i>Cephalalgia</i> , 2023, 43, 033310242211435.	1.8	2

#	ARTICLE	IF	CITATIONS
728	Pharmacologic prevention of migraine. <i>Cmaj</i> , 2023, 195, E187-E192.	0.9	5
729	A potential role for onabotulinumtoxinA in the management of Hallucinogen persisting perception disorder. <i>Australasian Psychiatry</i> , 2023, 31, 230-231.	0.4	1
730	Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine. <i>Practical Neurology</i> , 2023, 23, 200-207.	0.5	1
731	Botulinum neurotoxin is both poison and medicine: botulinum therapy and iatrogenic botulism. <i>Epidemiology and Infectious Diseases (Russian Journal)</i> , 2023, 27, 341-359.	0.1	1
732	Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review. <i>Life</i> , 2023, 13, 665.	1.1	1
734	Effectiveness of anti-CGRP monoclonal antibodies in the preventive treatment of migraine: A prospective study of 63 patients. <i>Medicina Clínica (English Edition)</i> , 2023, , .	0.1	1
735	PrÃ©vention pharmacologique de la migraine. <i>Cmaj</i> , 2023, 195, E559-E565.	0.9	0
736	Quantitative and Qualitative Pain Evaluation in Response to OnabotulinumtoxinA for Chronic Migraine: An Observational Real-Life Study. <i>Toxins</i> , 2023, 15, 284.	1.5	1
761	Chronic migraine and medication overuse. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2023, , 187-200.	1.0	1
764	Management of medication overuse headache. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2024, , 277-299.	1.0	0
765	Evidence-based preventive treatment of migraine. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2024, , 219-241.	1.0	0
767	OnabotulinumtoxinA: Discussion of the evidence for effectiveness of OnabotulinumA and its place in chronic migraine treatment. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2024, , 87-106.	1.0	0
768	The evolving concept of multimorbidity and migraine. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2024, , 535-566.	1.0	0
774	Management of migraine in children and adolescents. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2024, , 487-502.	1.0	0